"The most common misconception among doctors and the general
public regarding medical Marijuana is that its effectiveness claims
are substantiated only by compelling anecdotes from patients," Aggarwal told SF Weekly. "What is not acknowledged is that 33
separate controlled clinical trials with patients -- at least a third
of which are of gold standard design -- have been conducted
and published in the United States by investigators at major
research centers using the same federal cannabis supply and mode of
colleagues write, "nearly all of the 33 published controlled clinical
trials conducted in the United States have shown significant and
measurable benefits in subjects receiving the treatment."
the article documents the growing acceptance of the therapeutic use of
Marijuana among organized medicine groups. More than 7,000 American
physicians (in the 13 states where medical Marijuana is legal) have
signed medical Marijuana authorizations for a total of 400,000
patients, according to Aggarwal and colleagues.
absent from medical Marijuana patients in the published trials -- and
in glaring contrast to opiate drugs -- are withdrawal symptoms and
other signs of drug dependence. Adverse effects were relatively rare,
and "the vast majority of reported adverse effects were not serious...
It is clear that as an analgesic, cannabis is extremely safe with
regarding Marijuana still remains widespread, even in the medical
community, according to the article. "There remains a near complete
absence of education about cannabinoid medicine in any level of medical
training," Aggarwal writes.
the most thorough review of the literature on medical Marijuana since
the Institute of Medicine report over a decade ago, with a trove of
data that wasn't available to the IOM," said Rob Kampia, executive
director of the Marijuana Policy Project, which works for legalization.
"It is simply incomprehensible that a medicine that is so clearly safe
and effective remains banned from medical use by federal law and the
laws of 37 states."
Marijuana is classified as a Schedule I drug, defining it as having
high potential for abuse, unsafe for use even under medical
supervision, and lacking currently accepted uses in the U.S.